Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma

Frontiers in Immunology

Immunology

Tong Wang¹  Xiaoying Qian¹  Yong Li¹  Xinwei Zhang¹  Biao Yu¹  Shangkun Yuan¹  Yong Wang¹  Renfang Chen¹  Chen Fang¹  Zhimin Zeng²  Anwen Liu²  Yan Yin³  Fanrong Liu⁴  Yong Yuan⁵ 

[1] Department of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China;Medical Innovation Center, The First Affiliated Hospital of Nanchang University, Nanchang, China;Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China;Jiangxi Key Laboratory of Clinical Translational Cancer Research, Nanchang, Jiangxi, China;Radiation Induced Heart Damage Institute of Nanchang University, Nanchang, Jiangxi, China;Department of Pathology, The First Affiliated Hospital of Nanchang University, Nanchang, China;Department of Pathology, The Second Affiliated Hospital of Nanchang University, Nanchang, China;Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China;

关键词: pulmonary sarcomatoid carcinoma;    immune checkpoint inhibitors;    immunotherapy;    anlotinib;    camrelizumab;    tislelizumab;   

DOI  :  10.3389/fimmu.2023.1269596

 received in 2023-07-30, accepted in 2023-08-24,  发布年份 2023

来源: Frontiers

【 授权许可】

Unknown   
Copyright © 2023 Zeng, Qian, Liu, Wang, Yuan, Fang, Zhang, Yuan, Chen, Yu, Wang, Yin, Li and Liu